U.S. Measles Case Count Up to 41 in 2024
There was only a total of 58 cases in 2023.
There have been 41 cases of measles in the U.S. this year, according to the weekly update by the Centers for Disease Control and Prevention.
The report from Feb. 29 states that cases have been reported in Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, Michigan, Minnesota, Missouri, New Jersey, New York City, Ohio, Pennsylvania, Virginia and Washington.
If this trend continues, this year’s numbers will soon surpass last year's – only 58 measles cases were reported for 2023. The biggest spike was seen during the week of Dec. 24 with 11 cases.
In 2020, there were only 13 cases reported, likely due to social distancing rules put in place during the COVID-19 pandemic.
The last large outbreak occurred in 2019, with a record 1,274 cases across 31 states, making it the highest number since 1992.
Measles (rubeola) is a highly contagious respiratory virus that has the potential to become deadly. It is still one of the most common respiratory diseases in the world, but thanks to vaccines, numbers in the United States have gone down tremendously. Before the first vaccine was developed in 1963, 3 to 4 million people in the U.S. got measles each year, according to the FDA.
Most people who get the most common two-dose version of the vaccine will never get the disease, even if they’ve been exposed. However, cases are on the rise due to a combination of the growing suspicion of vaccines and an increase in international travel.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
